Find a study

📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →

This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

📍 University of Missouri Hospital · Columbia, MO · Get directions →

Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

📍 Eczema Treatment Center of New Jersey · East Windsor, NJ · Get directions →

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →

This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

📍 Lurie Children's Hospital/Northwestern University · Chicago, IL · Get directions →

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

📍 University of Michigan · Ann Arbor, MI · Get directions →

Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.

📍 University of California, San Francisco · San Francisco, CA · Get directions →

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.